MGMT and gliosarcoma: Heatmaps indicating methylation levels of individual CpGs in enhancers A–I and the MGMT promoter and MGMT protein expression levels for patient-derived tumor cells (PDCs) from 37 glioblastoma patients and one gliosarcoma patient and the commercially available glioblastoma cell line T98G are shown in Figure 1.